See more : LF Corp. (093050.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Dynavax Technologies Corporation (DVAX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Dynavax Technologies Corporation, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Invincible Investment Corporation (8963.T) Income Statement Analysis – Financial Results
- Religare Enterprises Limited (RELIGARE.NS) Income Statement Analysis – Financial Results
- eGalax_eMPIA Technology Inc. (3556.TWO) Income Statement Analysis – Financial Results
- RYU Apparel Inc. (RYPPF) Income Statement Analysis – Financial Results
- Pearl Holdings Acquisition Corp (PRLH) Income Statement Analysis – Financial Results
Dynavax Technologies Corporation (DVAX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.dynavax.com
About Dynavax Technologies Corporation
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 232.28M | 722.68M | 439.44M | 46.55M | 35.22M | 8.20M | 327.00K | 11.04M | 4.05M | 11.03M | 11.25M | 9.71M | 21.61M | 23.95M | 40.32M | 37.09M | 14.09M | 4.85M | 14.66M | 14.81M | 826.00K | 1.43M | 2.36M | 0.00 |
| Cost of Revenue | 50.17M | 262.15M | 173.57M | 13.91M | 19.39M | 21.80M | 1.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 299.00K | 980.00K | 980.00K | 980.00K | 1.00M | 698.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 182.12M | 460.53M | 265.87M | 32.64M | 15.83M | -13.60M | -867.00K | 11.04M | 4.05M | 11.03M | 11.25M | 9.71M | 21.32M | 22.97M | 39.34M | 36.11M | 13.09M | 4.15M | 14.66M | 14.81M | 826.00K | 1.43M | 2.36M | 0.00 |
| Gross Profit Ratio | 78.40% | 63.73% | 60.50% | 70.12% | 44.95% | -165.87% | -265.14% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 98.62% | 95.91% | 97.57% | 97.36% | 92.88% | 85.60% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 54.89M | 46.60M | 32.23M | 28.61M | 62.33M | 74.95M | 64.99M | 84.49M | 86.94M | 84.58M | 50.87M | 49.15M | 51.32M | 53.68M | 38.71M | 44.77M | 65.89M | 50.12M | 27.89M | 23.13M | 14.38M | 15.97M | 17.36M | 8.27M |
| General & Administrative | 152.95M | 131.41M | 100.16M | 79.26M | 48.72M | 64.77M | 27.37M | 37.26M | 22.18M | 17.76M | 26.87M | 28.16M | 17.57M | 16.88M | 15.75M | 15.46M | 18.29M | 14.84M | 9.26M | 8.54M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 24.76M | 26.27M | 31.76M | 7.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 152.95M | 131.41M | 100.16M | 79.26M | 74.99M | 64.77M | 27.37M | 37.26M | 22.18M | 17.76M | 26.87M | 28.16M | 17.57M | 16.88M | 15.75M | 15.46M | 18.29M | 14.84M | 9.26M | 8.54M | 4.21M | 4.12M | 4.53M | 3.45M |
| Other Expenses | 11.31M | 7.80M | 8.66M | 6.81M | 3.35M | -70.00K | -486.00K | -2.49M | 317.00K | 433.00K | -348.00K | -293.00K | 299.00K | 980.00K | 980.00K | 980.00K | 1.00M | 698.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 219.15M | 178.01M | 132.38M | 107.86M | 137.32M | 139.72M | 93.55M | 121.75M | 109.12M | 102.34M | 77.74M | 77.31M | 69.19M | 71.54M | 55.43M | 61.21M | 85.19M | 65.65M | 37.15M | 31.67M | 18.59M | 20.09M | 21.89M | 11.72M |
| Cost & Expenses | 269.31M | 440.16M | 305.96M | 121.77M | 156.71M | 161.52M | 93.55M | 121.75M | 109.12M | 102.34M | 77.74M | 77.31M | 69.19M | 71.54M | 55.43M | 61.21M | 85.19M | 65.65M | 37.15M | 31.67M | 18.59M | 20.09M | 21.89M | 11.72M |
| Interest Income | 31.99M | 7.91M | 140.00K | 1.26M | 3.37M | 3.83M | 1.34M | 755.00K | 205.00K | 191.00K | 116.00K | 291.00K | 103.00K | 85.00K | 112.00K | 1.74M | 4.17M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 6.76M | 6.73M | 11.18M | 19.06M | 16.98M | 9.34M | 0.00 | 0.00 | 572.00K | 35.00K | 0.00 | 2.35M | 1.96M | 1.65M | 124.00K | 9.16M | 1.72M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 7.28M | 6.67M | 7.01M | 9.34M | 21.53M | 14.48M | 4.44M | 2.26M | 1.37M | 1.40M | 1.33M | 1.21M | 1.60M | 2.40M | 2.84M | 2.83M | 632.00K | 1.53M | 3.13M | 3.27M | 576.00K | 678.00K | 0.00 | -2.05M |
| EBITDA | 9.67M | 307.70M | 95.71M | -46.84M | -114.09M | -135.08M | -90.72M | -110.19M | -104.86M | -89.28M | -65.39M | -66.39M | -45.04M | -53.26M | -12.17M | -21.29M | -71.09M | -60.67M | -19.36M | -15.44M | -17.19M | -17.98M | -19.53M | -11.72M |
| EBITDA Ratio | 4.16% | 41.27% | 32.38% | -144.26% | -325.87% | -1,824.36% | -27,292.05% | -1,002.51% | -2,581.51% | -822.04% | -579.16% | -695.88% | -216.57% | -154.67% | -30.45% | -70.87% | -497.32% | -1,136.60% | -132.09% | -91.73% | -2,080.87% | -1,260.06% | -827.94% | 0.00% |
| Operating Income | -37.03M | 283.52M | 134.49M | -75.22M | -121.49M | -153.32M | -96.01M | -110.71M | -105.07M | -91.31M | -66.49M | -67.60M | -47.58M | -47.59M | -15.12M | -24.12M | -71.09M | -64.98M | -22.49M | -16.86M | -17.76M | -18.66M | -19.53M | -9.66M |
| Operating Income Ratio | -15.94% | 39.23% | 30.60% | -161.59% | -344.95% | -1,870.20% | -29,359.33% | -1,002.51% | -2,594.40% | -827.69% | -590.95% | -695.86% | -220.12% | -198.70% | -37.49% | -65.02% | -504.45% | -1,340.68% | -153.46% | -113.83% | -2,150.61% | -1,307.57% | -827.94% | 0.00% |
| Total Other Income/Expenses | 32.66M | 10.78M | -56.97M | -6.87M | -17.76M | -5.58M | 851.00K | -1.74M | -1.72M | 589.00K | -232.00K | -2.35M | -1.02M | -9.72M | -12.00K | -2.42M | 2.45M | 3.19M | 1.94M | 889.00K | -274.00K | 0.00 | 19.53M | 0.00 |
| Income Before Tax | -4.37M | 294.30M | 77.52M | -75.24M | -152.60M | -158.90M | -95.15M | -112.44M | -106.79M | -90.72M | -66.72M | -69.95M | -48.60M | -57.31M | -30.57M | -20.83M | -59.97M | -52.05M | -20.56M | -15.97M | -18.04M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -1.88% | 40.72% | 17.64% | -161.63% | -433.29% | -1,938.27% | -29,099.08% | -1,018.24% | -2,636.89% | -822.35% | -593.01% | -720.08% | -224.84% | -239.28% | -75.81% | -56.15% | -425.54% | -1,073.90% | -140.26% | -107.82% | -2,183.78% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 2.02M | 1.14M | 808.00K | 16.54M | -1.20M | 3.76M | 1.45M | -3.01M | -476.00K | -936.00K | -116.00K | 851.00K | 1.02M | 9.72M | 0.00 | -3.29M | 372.00K | -8.75M | 0.00 | 0.00 | -686.00K | -621.00K | 18.41M | 17.06M |
| Net Income | -6.39M | 293.16M | 76.71M | -91.78M | -151.40M | -158.90M | -95.15M | -112.44M | -106.79M | -90.72M | -66.72M | -69.95M | -48.60M | -57.31M | -30.57M | -20.83M | -59.97M | -52.05M | -20.56M | -15.97M | -17.35M | -18.04M | -18.41M | -26.72M |
| Net Income Ratio | -2.75% | 40.56% | 17.46% | -197.15% | -429.87% | -1,938.27% | -29,099.08% | -1,018.24% | -2,636.89% | -822.35% | -593.01% | -720.08% | -224.84% | -239.28% | -75.81% | -56.15% | -425.54% | -1,073.90% | -140.26% | -107.82% | -2,100.73% | -1,264.05% | -780.50% | 0.00% |
| EPS | -0.05 | 2.32 | 0.62 | -0.91 | -2.10 | -2.55 | -1.81 | -2.92 | -3.25 | -3.45 | -3.40 | -4.10 | -3.88 | -6.95 | -7.57 | -5.23 | -15.09 | -16.10 | -7.93 | -7.54 | -96.88 | -106.04 | -122.91 | -225.90 |
| EPS Diluted | -0.05 | 1.97 | 0.54 | -0.91 | -2.10 | -2.55 | -1.81 | -2.92 | -3.25 | -3.45 | -3.40 | -4.10 | -3.88 | -6.95 | -7.57 | -5.23 | -15.09 | -16.10 | -7.93 | -7.54 | -96.24 | -106.04 | -122.91 | -225.90 |
| Weighted Avg Shares Out | 128.73M | 126.40M | 116.26M | 100.75M | 72.02M | 62.36M | 52.61M | 38.51M | 32.88M | 26.29M | 19.63M | 17.05M | 12.51M | 8.25M | 4.04M | 3.98M | 3.97M | 3.23M | 2.59M | 2.12M | 179.10K | 170.10K | 149.80K | 118.30K |
| Weighted Avg Shares Out (Dil) | 128.73M | 150.80M | 133.01M | 100.75M | 72.02M | 62.36M | 52.61M | 38.51M | 32.88M | 26.29M | 19.63M | 17.05M | 12.51M | 8.25M | 4.04M | 3.98M | 3.97M | 3.23M | 2.59M | 2.12M | 180.30K | 170.10K | 149.80K | 118.30K |
Does Dynavax Technologies (DVAX) Have the Potential to Rally 93.52% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 93.5% in Dynavax Technologies (DVAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into...
Dynavax to Present at the 7th Annual Evercore HealthCONx Conference
EMERYVILLE, Calif. , Nov. 26, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3 at...
Dynavax Technologies: What The Stock Buyback Means. What It Doesn't
Today, we revisit Dynavax Technologies Corporation, whose shares have moved up nicely after the company announced a significant buyback authorization. In addition, DVAX's flagship product Heplisav-B continues to increase market share consistently in a growing market. The company has also...
Dynavax Technologies (DVAX) Upgraded to Buy: Here's Why
Dynavax Technologies (DVAX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Predict an 88.32% Upside in Dynavax Technologies (DVAX): Here's What You Should Know
The consensus price target hints at an 88.3% upside potential for Dynavax Technologies (DVAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an...
Dynavax Announces $100 Million Accelerated Share Repurchase Program
EMERYVILLE, Calif. , Nov. 11, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that it has entered into an Accelerated Share Repurchase transaction ("ASR") under an agreement with Goldman Sachs...
Dynavax Technologies (DVAX) Q3 Earnings Surpass Estimates
Dynavax Technologies (DVAX) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.10 per share a year ago.
Dynavax Reports Third Quarter 2024 Financial Results and Provides Business Updates
HEPLISAV-B ® quarterly net product revenue of $79.3 million, representing 27% year-over-year growth Hepatitis B adult vaccine market expected to expand to a peak of over $900 million by 2030, with HEPLISAV-B expected to achieve at least 60% estimated total...
Dynavax Announces $200 Million Share Repurchase Program
EMERYVILLE, Calif. , Nov. 7, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced its Board of Directors has authorized the repurchase of up to $200 million of the Company's common stock.
Glancy Prongay & Murray LLP Announces Investigation of Dynavax Technologies Corporation (DVAX)
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Dynavax Technologies Corporation (Nasdaq: DVAX) concerning the Company and its directors' and officers' possible violations of state laws. If you own Dynavax stock, would like to learn more...
Source: https://incomestatements.info
Category: Stock Reports